TransGLYCIT® Remodeling Afucosylated G2 1 mg
Glycan remodeling of 1 mg human IgG with the G2 glycoform and core afucosylation
TransGLYCIT is a platform technology that enables efficient and site-specific human IgG glycan remodeling. With TransGLYCIT, antibodies with defined and homogenous glycoforms are generated using fast and robust enzymatic workflows.
TransGLYCIT contains all material needed to perform glycan remodeling of up to 1 mg IgG with the G2 glycoform and core afucosylation.
Legal & Disclaimers
All rights reserved. Genovis products may be covered by one or more patents, trademarks and copyrights owned by Genovis AB or licensed from third parties. For more information about commercial rights, please contact the Genovis team at licensing@genovis.com.
Genovis products are intended for research use only. They are not intended to be used for therapeutic or diagnostic purposes in humans or animals. All goods and services are sold subject to Genovis’ General Terms and Conditions of Sale.
© Genovis AB